Skip to main content
. Author manuscript; available in PMC: 2008 Feb 6.
Published in final edited form as: Pharmacoeconomics. 2006;24(11):1101–1119. doi: 10.2165/00019053-200624110-00007

Figure 8. Structure of the model used to evaluate the cost-effectiveness of alternative uses of Glycoprotein IIb/IIIa antagonists in acute coronary syndrome in the UK.

Figure 8

Source: Palmer et al. International Journal of Cardiology 2005; 100: 229-240.